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Abstract
Background: In the distal left main (LM) atherosclerosis mainly develops within bifurcation or trifur-
cation. The aim of this study was to analyze the strategy of distal LM stenosis treatment and associated 
clinical outcomes in a large hospital in Northern Poland.
Methods: The study population consisted of consecutive patients with stable coronary artery disease or 
acute coronary syndrome (ACS) and distal LM stenosis who were hospitalized between June 2012 and 
June 2013. Patients were treated with regular drug-eluting stents (rDES), including bioresorbable vascular 
scaffolds, or dedicated bifurcation stents (BiOSS LIM®). Clinical outcomes were analyzed at 12, 24 and 
36 months. Primary endpoint was cumulative major adverse cardiovascular events (MACE) inducing 
rate of cardiac death, myocardial infarction, and target lesion revascularization (TLR) after 36 months.
Results: One hundred and two patients were identified, 90 of whom were treated with percutaneous 
coronary intervention (56 rDES, including 9 Absorb, and 34 BiOSS) with no stent implantation fail-
ure. In 15 (16.7%) patients rDES was required within side branch (SB). After 36 months MACE rate 
was 19.0% (BiOSS: 18.8% vs. rDES 19.2%), whereas TLR rate was 10.7% (BiOSS 12.5% vs. rDES 
9.6%). In logistic regression for 36-month TLR rate proximal optimization technique (OR 0.311, 95% 
CI 0.211–0.644) was a prognostic factor of better clinical outcome, whereas non-ST-elevation ACS (OR 
2.211, 95% CI 1.642–5.110), ST-elevation myocardial infarction (OR 2.771, 95% CI 1.325–7.209) and 
SB stenting (OR 1.141, 95% CI 1.002–1.881) were risk factors of poor outcome.
Conclusions: Regular drug-eluting stents as well as dedicated bifurcation BiOSS LIM® stents enabled 
a simple and fast distal LM treatment option with a single stent. Both resulted in comparable MACE 
and TLR rates. (Cardiol J 2018; 25, 2: 188–195)
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Introduction
Results of randomized trials and observational 
studies showed that percutaneous coronary inter-
vention (PCI) is a potential alternative to bypass 
surgery for patients with unprotected left main 
(LM) coronary artery stenosis [1, 2]. Moreover, 
2 recent meta-analyses showed that primary endpoint 
of 1-year major adverse cardiac and cerebral events 
was non-significantly different in PCI group compared 
with the coronary artery bypass grafting (CABG) 
one, 14.5% and 11.8%, p = 0.11, respectively [3–5].
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In most cases atherosclerosis develops in the 
distal part of LM within bifurcation or trifurcation [6]. 
In general, based on non-randomized studies and 
extrapolations from the results of non-LM bifur-
cation trials, the provisional 1-stent approach has 
been considered  a preferred strategy over the 
elective 2-stent technique for patients with LM 
bifurcation disease. In practice, however, 2-stent 
techniques are chosen more frequently for LM bi-
furcation than for non-LM lesions due to concerns 
regarding the ischemic myocardial volume, which 
would be jeopardized by adverse events [7].
The aim of this study was to analyze the strategy 
of distal LM stenosis treatment and associated clini-
cal outcomes in a large hospital in Northern Poland.
Methods
Study population and study design
It was a retrospective registry conducted 
between June 2012 to June 2013 in a high-volume 
center (> 1500 PCI per year) in Poland (Olsztyn). 
The local database was searched for patients with 
LM stenosis treatment on 12.09.2016. The inclu-
sion criteria were: age ≥ 18 years old and distal 
LM stenosis qualified for PCI. Present CABG 
treatment was the exclusion criterion. All patients 
with symptomatic stable coronary artery disease 
(CAD), non ST-elevation acute coronary syndrome 
(NSTE-ACS) as well as ST-elevation myocardial in-
farction (STEMI) were taken into account. Patients 
were contacted by telephone to obtain follow-up 
data. The Institutional Review Board approved the 
study protocol. 
Interventional procedure  
and concomitant medications
Single stent implantation was the default 
strategy [8]. Bifurcation lesions were assessed 
according to Medina classification using an index of 
1 for stenosis greater than 50% and 0 for no steno-
sis (visual estimation) [9]. There was no restriction 
regarding lesion length in patient selection. The 
main indication for using dedicated bifurcation 
stents was the ratio of proximal main vessel (MV) 
diameter to distal MV diameter > 1.2. If required, 
additional regular DES (rDES) was implanted. 
A stent in the side branch (SB) was implanted only 
if there was a proximal residual stenosis greater 
than 70% after balloon dilatation and/or a significant 
flow impairment after proximal MV — distal MV 
stenting and/or a flow limiting dissection. 
In patients with STEMI or NSTE-ACS loading 
dose of clopidogrel (600 mg), ticagrelor (180 mg) 
or prasugrel (60 mg) was given, and, if also needed, 
a loading dose of acetylsalicylic acid (ASA) was 
applied (300 mg). In planned procedures 72 h be-
fore PCI each patient received ASA (75 mg/24 h) 
and clopidogrel (75 mg/24 h). All procedures were 
performed in a standard way via radial or femoral 
access using 6 Fr or 7 Fr guiding catheters. After 
insertion of the arterial sheath each patient received 
unfractionated heparin (70–100 IU/kg). Additional 
bolus was given to maintain activated clotting time 
> 250 s. Dual antiplatelet therapy (ASA 75 mg q.d. 
and clopidogrel 75 mg q.d., prasugrel 10 mg q.d. or 
ticagrelor 90 mg b.i.d.) was prescribed for 12 months. 
All patients had troponin I, creatine kinase 
(CK) and CK-MB levels examined before the pro-
cedure, 6 h and 24 h afterwards. Periprocedural 
myocardial infarction (MI; type 4a) was assessed 
according to the third universal definition [10]. 
Device description
Second generation drug-eluting stents (DES) 
available in the cath lab, Absorb bioresorbable vas-
cular scaffold (BVS) (Abbott, USA) and dedicated 
bifurcation stent BiOSS LIM® (Balton, Poland) 
could have been used [11]. 
Endpoints
The primary endpoint was the cumulative rate of 
major adverse cardiovascular events (MACE) includ-
ing cardiac death, MI and repeated revascularization 
of the target lesion (TLR) at 3 years. The secondary 
endpoints included cardiac death, all-cause death, MI, 
and TLR at 1-, 2- and 3-year follow-up. All deaths 
were deemed cardiac unless proven otherwise. 
Statistical analysis
Continuous variables were presented as mean 
± standard deviation. Categorical data were pre-
sented as numbers (%). Continuous variables were 
compared using an unpaired Student t test, and 
categorical data using the c2 test or Fisher exact 
test, as appropriate. If distribution was not normal, 
Wilcoxon signed-rank tests and Mann-Whitney 
U-tests were used. P values of < 0.05 were con-
sidered statistically significant. Also, univariate 
and multivariate logistic regression analysis were 
performed. Statistical analyses were performed us-
ing R 3.0.2 for OS (R Foundation, Vienna, Austria).
Results
Baseline clinical characteristics
Between June 2012 and June 2013 102 pa-
tients with distal LM stenosis were identified. 
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Nevertheless, 90 patients were qualified for PCI 
and only those patients were further analyzed 
(12 patients were referred to CABG). The mean 
age was 65.6 ± 8 years and women stand for 26.7% 
(n = 24) of the population. Most patients had sta-
ble CAD (n = 59, 65.5%), hypertension (n = 78, 
86.7%) and dyslipidemia (n = 81, 90%). The de-
tailed data are presented in Table 1.
Angiographic and procedural  
characteristics
The bifurcation lesions were most frequently 
assessed as type B2 (n = 57, 63.3%), and true 
bifurcations stand for 46 (51.1%) treated lesions. 
Only DES were deployed among which most fre-
quently rDES were used (n = 56, 62.2%), including 
bioresorbable vascular scaffold systems (n = 9), 
and were followed by dedicated bifurcation BiOSS 
LIM stents (n = 34, 37.8%) (Table 2).
The main procedural aspects are presented in 
Table 3. All stents were successfully implanted. 
In 15 (16.7%) cases the additional stent was im-
planted into the SB, mainly using T-and-protrusion 
Table 1. Demographics.
Parameter No. of patients
n = 90 (%)
Age [years] 65.6 ± 8.0
Women 24 (26.7%)
Stable CAD 59 (65.5%)
NSTE-ACS 27 (30%)
STEMI 4 (2.5%)
Hypertension 78 (86.7%)
Dyslipidemia 81 (90%)
Diabetes type 2 33 (36.7%)
Prior MI 60 (66.7%)
Prior PCI 54 (60%)
Prior CABG 33 (36.7%)
Lower extremity artery disease 9 (10%)
Carotid artery disease 9 (10%)
Chronic kidney disease 12 (13.3%)
Smoking 27 (30%)
CABG — coronary artery bypass graft; CAD — coronary artery  
disease; NSTE-ACS — non-ST-elevation acute coronary syndrome; 
MI — myocardial infarction; PCI — percutaneous coronary  
intervention
Table 2. Lesion and stent characteristics.
Lesion characteristics No. of lesions 
n = 90 (%)
Medina type:
1.1.1. 15 (16.7%)
1.1.0. 24 (26.7%)
1.0.1. 13 (14.4%)
0.1.1. 18 (20.0%)
1.0.0. 14 (15.6%)
0.1.0 6 (6.7%)
SYNTAX score 22.39 ± 7.48
Lesion type:
A 0 (0%)
B1 5 (5.6%)
B2 57 (63.3%)
C 28 (31.1%)
Stent type:
Regular DES: 56 (62.2%)
Sirolimus eluting stent 29 (32.2%)
Everolimus eluting stent 18 (20.0%)
Bioresorbable vascular scaffold 9 (10.0%)
Dedicated bifurcation stent BiOSS LIM 34 (37.8%)
DES — drug eluting stent
Table 3. Procedural characteristics.
Parameter No. of lesions 
n = 90 (%)
Successful implantation 90 (100%)
Main vessel predilatation 69 (76.7%)
Side branch predilatation 45 (50.0%)
Both branches predilatation 9 (10.0%)
Regular DES nominal  
parameters [mm]
3.79 ± 0.45  
× 17.0 ± 6.60
Dedicated bifurcation stent  
nominal parameters  
(proximal diameter × distal  
diameter × length) [mm]
3.98 ± 0.32  
× 3.23 ± 0.33  
× 16.92 ± 2.99
Side branch postdilatation 33 (36.7%)
Proximal optimization technique 51 (56.7%)
Final kissing balloon 39 (43.3%)
Additional stent in side branch 15 (16.7%)
Fluoroscopy time [min] 18.8 ± 10.6
Contrast volume [mL] 244 ± 150
Vascular access femoral/radial 6.7%/93.3%
Guiding catheter 6 F/7 F 100%/0%
Double-stent technique: N = 15 (%)
T-stenting  2 (13.3%)
T-and-protrusion technique 7 (46.7%)
Mini-crush 2 (13.3%)
Culotte 4 (26.7%) 
DES — drug-eluting stent
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or culotte techniques. Final kissing balloon ended 
43.3% of procedures.
Clinical outcomes
During the in-hospital period 6 deaths oc-
curred. They were caused by: multi-organ failure 
as a result of persisting cardiogenic shock (n = 5) 
or cardiac tamponade as a result of free wall rup-
ture (n = 1). Therefore, in further analysis only 84 
patients were taken into consideration. No acute 
stent thrombosis was observed. 
Clinical follow-up data were available in all 
patients at 12, 24 and 36 months (Table 4). At 
3 years (median: 35 months, interquartile range 
[IQR] 32–39 months) the MACE incidence was 19% 
(n = 16). There were 2 cardiac deaths (heart failure 
deterioration), 3 deaths caused by cancer (lung 
cancer — 2, pancreas cancer — 1), 5 cases of MI 
(MI caused by lesions within deployed stents — 
2 cases and lesions in other vessels — 3 cases) 
and 9 (10.7%) TLR cases. Seven TLR cases were 
treated with PCI, and 2 patients were referred for 
CABG. There were no statistical differences be-
tween BiOSS LIM stents, sirolimus-eluting stents, 
everolimus-eluting metallic stents and Absorb BVS 
stents in terms of MACE or TLR rates (Table 5). 
Logistic regression analysis
Table 6 and Table 7 presents logistic regres-
sion analyses for MACE and TLR, respectively. 
In multivariate analysis regarding MACE rate 
NSTE-ACS and STEMI were associated with 
worse clinical outcome. And in the case of TLR 
rate in regression analysis, NSTE-ACS, STEMI 
and SB stenting were associated with worse clini-
cal outcome, but proximal optimization technique 
(POT) was associated with better clinical outcome. 
Discussion
The main findings of this paper are: 1) dis-
tal LM stenosis was mainly treated with 1 stent 
(provisional T-stenting [PTS]), 2) 3-year MACE 
and TLR rates were 19% and 10.7%, respectively, 
3) the clinical outcomes between dedicated bi-
furcation stents BiOSS and rDES were similar, 
4) optimization techniques, especially POT, im-
proved clinical outcomes.
The continuous advancement of angioplasty 
procedures broadens the range of lesions, which 
could be safely treated with PCI. Bifurcation ste-
nosis in distal LM stem is one of such cases and 
its rate is systematically increasing in the popula-
tion of patients subjected to PCI [12]. This study 
showed a high rate of device success (100%) with 
favorable acute and long-term clinical results ex-
pressed by MACE rate at 12 as well as 36 months, 
9.5% and 19%, respectively. It is worth mentioning 
that in the original paper by Serruys et al. [13], 
12-month cumulative rate of major adverse car-
diac or cerebrovascular events in a population of 
patients with low SYNTAX score (0–22) was 14.7% 
and with intermediate SYNTAX score (23–32) 
— 16.7%. Also, the present results are in agree-
ment with recently published 3-year results of the 
EXCEL trial, in which MACE and TLR rates were 
18.2% and 9.5%, respectively [2]. Moreover, the 
present study population was severely diseased, 
with a rate of diabetes (36.7%), prior MI (66.7%) 
and prior PCI (60%) higher than in other studies 
assessing bifurcation treatment, respectively, 
11–25.7%, 19.5–46% and 11.3–37.1% [13–18].  
European Bifurcation Club recommends pro-
visional SB stenting as standard strategy for treat-
ment of coronary bifurcation. Although there are 
lesions for which PTS is not an optimal approach, 
the need for an alternative strategy is relatively 
rare in most lesions. Similar results were obtained 
in the presented registry, most bifurcations (83.3%) 
were treated with PTS strategy and of importance 
is that 51.1% of cases were true bifurcations. As it 
was proved earlier PTS strategy ensures the best 
angiographic and clinical outcomes in a majority 
of studies [14]. Moreover, Kim et al. [7] as well as 
Table 4. Clinical results.
1-year FU (n = 84) 2-year FU (n = 84) 3-year FU (n = 84)
MACE 8 (9.5%) 12 (14.3%) 16 (19.0%)
All-cause death 2 (2.4%) 3 (3.6%) 5 (5.9%)
Cardiac death 1 (1.2%) 2 (2.4%) 2 (2.4%)
Myocardial infarction 2 (2.4%) 3 (3.6%) 5 (5.9%)
Stent thrombosis 0 (0%) 0 (0%) 0 (0%)
Target lesion revascularization 5 (5.9%) 7 (8.3%) 9 (10.7%)
FU — follow-up; MACE — major adverse cardiovascular events
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Table 5. Three-year clinical results — subgroup analysis.
Parameter Three-year follow-up
Whole  
(n = 84)
BiOSS LIM  
(n = 32)
SES  
(n = 26)
EES  
(n = 17)
BVS  
(n = 9)
MACE 16 (19.0%) 6 (18.8%) 6 (23.1%) 3 (17.6%) 1 (11.1%)
All-cause death 5 (5.9%) 1 (3.1%) 3 (11.5%) 0 (0%) 1 (11.1%)
Cardiac death 2 (2.4%) 1 (3.1%) 0 (0%) 1 (5.9%) 0 (0%)
Myocardial infarction 5 (5.9%) 1 (3.1%) 2 (7.7%) 1 (5.9%) 1 (11.1%)
Target lesion revascularization 9 (10.7%) 4 (12.5%) 4 (15.4%) 1 (5.9%) 0 (0%)
BVS — bioresorbable vascular scaffold; EES — metallic everolimus-eluting stent; MACE — major adverse cardiovascular events; SES — metallic 
sirolimus eluting stent
Table 6. Logistic regression for major adverse cardiovascular events at 3-year follow-up.
Variate Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
BiOSS vs. DES 0.958 (0.721–1.355) 0.634
Sex: female vs. male 0.821 (0.490–1.331) 0.542
Age [increase per 1 year] 1.213 (0.693–1.459) 0.365
NSTE-ACS 1.770 (1.390–2.879) 0.005 1.922 (1.441–4.210) 0.038
STEMI 2.365 (1.772–4.222) 0.003 3.021 (2.321–6.409) 0.001
Diabetes mellitus 1.851 (1.281–2.169) 0.028
Prior MI 1.543 (0.780–2.004) 0.652
Prior PCI 1.329 (0.602–1.841) 0.411
Coronary artery bypass graft 1.201 (0.883–2.261) 0.653
Chronic kindey disease 1.781 (0.833–3.099) 0.201
True bifurcation 1.899 (1.004–2.102) 0.044
Side branch stenting 1.260 (0.778–1.901) 0.247
Fnal kissing balloon 0.722 (0.567–1.114) 0.061
Proximal optimization technique 0.882 (0.491–0.997) 0.042
CI — confidence interval; DES — drug eluting stent; MI — myocardial infarction; NSTE-ACS — non-ST-elevation acute coronary syndrome; 
STEMI — ST-elevation myocardial infarction; OR — odds ratio; PCI — percutaneous coronary intervention
Table 7. Logistic regression for target lesion revascularization at 3-year follow-up.
Variate Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
BiOSS vs. DES 0.923 (0.701–1.295) 0.441
Sex: female vs. male 0.781 (0.540–1.119) 0.622
Age [increase per 1 year] 1.331 (0.713–1.521) 0.431
NSTE-ACS 1.550 (1.430–2.121) 0.034 2.211 (1.642–5.110) 0.008
STEMI 2.198 (1.473–3.761) 0.015 2.771 (1.325–7.209) 0.001
Diabetes mellitus 1.651 (1.191–2.009) 0.018
Prior MI 1.553 (0.612–1.834) 0.772
Prior PCI 1.511 (0.709–1.927) 0.616
Coronary artery bypass graft 1.321 (0.893–2.012) 0.499
Chronic kidney disease 1.238 (0.653–2.387) 0.105
True bifurcation 1.669 (1.214–2.342) 0.034
Side branch stenting 1.345 (1.009–1.699) 0.047 1.141 (1.002–1.881) 0.042
Final kissing balloon 0.632 (0.437–0.991) 0.041
Proximal optimization technique 0.512 (0.322–0.799) 0.012 0.311 (0.211–0.644) 0.002
CI — confidence interval; DES — drug eluting stent; MI — myocardial infarction; NSTE-ACS — non-ST-elevation acute coronary syndrome; 
STEMI — ST-elevation myocardial infarction; OR — odds ratio; PCI — percutaneous coronary intervention
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others showed that one-stent technique is better 
than 2-stent technique [15].
There was a relatively low rate of stent im-
plantation in SB (16.7% of cases). This value is 
lower than in other studies, where the value ranges 
between 30% and 50% [16–18]. Only 15 cases re-
quired double stent technique, mainly performed 
with T-and-protrusion and culotte. Worth stressing 
is the fact that all culotte procedures were per-
formed in distal LM with 2 BiOSS LIM® stents as 
described previously (Fig. 1) [19]. 
Predilatation of MV prior to stenting is the 
common approach, when routine SB dilation is 
unnecessary. Nevertheless, in the presence of 
severe SB ostial stenosis it should be considered. 
In the presented registry MV predilatations were 
performed in 76.7% cases and SB predilatations 
in 50%. However, one has to keep in mind that 
the potential advantages of SB dilatation include 
increased ostial SB lumen, facilitated rewiring of 
the SB after stenting and avoidance of rewiring 
and post-dilatation of SB after implantation of  MV 
stent [20].
Appropriate stent apposition in the proximal 
MV is achieved by POT, which is performed by 
dilating the proximal MV stent from the proximal 
stent edge to just proximal to the carina, using 
a short oversized balloon. POT facilitates SB access, 
reduces risk of accidental abluminal rewiring, 
lowers the risk of stent distortion by catheter col-
lision, and enhances scaffolding at the SB ostium. 
Thus, POT should be considered a standard step 
in bifurcation treatment. Also final kissing balloon 
technique (FKB) optimizes the procedure [14]. 
Unfortunately, in the present paper  rates of POT 
and FKB were relatively low, 56.7% and 43.3%, 
respectively. This could be caused by the fact that 
only recently POT is strongly recommended by 
the European Bifurcation Club, and in cases of 
FKB — that only rarely 2-stent technique was 
used where FKB is obligatory. Also, in 37.8% of 
cases dedicated bifurcation BiOSS® stents were 
implanted. The stepped design of the BiOSS® 
stent delivery balloon theoretically was to ensure 
a FKB- and POT-like effect, thus allowing opera-
tors to frequently omit this part of the procedure. 
However, as was shown in POLBOS I trial not 
performing FKB and POT was associated with 
worse clinical outcomes and is a trend in larger 
late lumen loss, whereas in the NORDIC 3 study 
it was proved that FKB reduced angiographic side 
branch restenosis, especially in patients with true 
bifurcation lesions [21, 22]. These findings were 
confirmed in the MITO Registry [23]. Also, worth 
Figure 1. Two BiOSS stent implantation within distal 
left main; A, B. Initial views; C, D. First BiOSS LIM im-
plantation in left main-left circumflex artery (LM-LCx); 
E, F. Second BiOSS LIM implantation in the left main-left 
ascending dimension artery (LM-LAD); G. Final kissing 
balloon; H. Proximal optimization technique; I, J. Final 
views.
stressing is the fact that the negative impact of true 
bifurcation and positive impact of FKB on MACE 
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and TLR rates were also confirmed in our logistic 
regression analysis.
Although the procedure was performed on LM 
stenosis, most cases were performed via the radial 
access (93.3%) and 6 F when guiding catheter was 
used (93.3%). This approach was associated with 
less risk of complications, such as severe bleeding 
or the need for blood transfusion.
Also, in 10% of cases where BVS were used, 
all cases were uneventful. The use of bioresorbable 
stents might present potential advantages com-
pared with metallic DES for bifurcation treatment. 
Some limitations of currently available BVS, such 
as strut thickness and limited expansion capacity 
as well as the reports of increased late thrombosis 
influence the adoption of BVS as a standard strategy 
[24, 25]. Nevertheless, in the literature Absorb BVS 
was successfully deployed in the distal LM [26–28]. 
This registry has several limitations that should 
be acknowledged. First of all, the sample size was 
relatively small and heterogenous, additionally 
no sample size calculation was performed. Other 
limitations of this study are its non-randomized 
manner and all known drawbacks of retrospective 
studies. Moreover, intravascular ultrasound imag-
ing was used only in 27.8% of cases (n = 25), and 
mainly manual pullback was performed.
Conclusions
Percutaneous distal LM stenosis treatment is 
a safe and effective procedure, and PTS is the pre-
ferred technique. Both rDES as well as dedicated 
bifurcation stents BiOSS LIM® enabled a simple 
and fast bifurcation treatment option with a single 
stent and with comparable MACE and TLR rates.
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